Physicians' Academy for Cardiovascular Education

Lp(a)

Follow news, literature, education and expert opinions on the emerging role of Lp(a) as riks factor and therapeutic target in cardiovascular disease

Introduction: Lp(a), a new lipid frontier in CV risk management & target for therapy

10' education - Nov. 3, 2020 - Prof. Erik Stroes, MD

Is there a role for PCSK9 inhibition in patients with high Lp(a)?

10' education - Nov. 2, 2020 - Prof. Vera Bittner, MD

Novel strategies to lower Lp(a)

10' education - Oct. 27, 2020 - Prof. Sam Tsimikas, MD

Latest results with non-LDL lowering agents in reducing CV risk

10' education - Oct. 26, 2020 - Prof. Ulrich Laufs, MD

Why worry about high Lp(a) and how to assess Lp(a) levels?

10' education - Oct. 7, 2020 - Pia Kamstrup, MD, PhD

Familial Hypercholesterolemia and Lp(a)

10' education - July 14, 2020 - Nick Nurmohamed, MD

Treatment goals for LDL-c-lowering and emerging evidence for the importance of Lp(a)

10' education - May 26, 2020 - Prof. J. Wouter Jukema, MD - Leiden, The Netherlands

Assessing residual lipid risk with advanced testing

5' education - Feb. 17, 2020 - Samia Mora, MD

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD

The burden of residual CV risk in the statin era

5' education - Jan. 6, 2020 - Erin Bohula, MD

Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most?

10' education - Sep. 28, 2019 - Paris, France - Prof. Ph. Gabriel Steg, MD - Online CME

Are we ready for prime-time Lp(a) assay standardization?

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Santica Marcovina

LDL vs Lp(a) cholesterol: confounding

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Calvin Yeang, MD, PhD

Associations of Lp(a) with CV morbidity and mortality

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Pia Kamstrup, MD, PhD

Phase II data on Lp(a) lowering, followed by NHLBI recommendation

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Sam Tsimikas

Entry of Lp(a) into the CV arena

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Florian Kronenberg, MD

Lp(a) apheresis and CVD risk modulation

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Elisa Waldmann, MD

Prevalence and relevance of elevated Lp(a) in familial hypercholesterolemia

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Børge Nordestgaard, MD

Lp(a) and calcification in aortic stenosis

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Kang He Zheng, MD

Reduced Lp(a) with PCSK9 inhibitors in individuals with high Lp(a) at baseline contributes to CV risk reduction

3' education - May 29, 2019 - Maastricht. The Netherlands - Prof. Chapman, DSc

Targeting PCSK9 in clinical practice: Guidance & future

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands - Online CME

Lp(a) lowering with PCSK9 inhibitor not enough to tackle artery wall inflammation

3' education - Dec. 3, 2018 - Prof. Erik Stroes, MD

Lowering Lp(a) potently and safely with antisense technology

3' education - Nov. 20, 2018 - Sotirios Tsimikas, MD

PCSK9 inhibitors may represent the first therapeutic means to lower Lp(a)

3' education - June 29, 2018 - John Chapman - Paris, France

How much should Lp(a) be lowered to translate into meaningful CV benefit?

3' education - June 29, 2018 - Brian Ference, MD - Cambridge, UK

Advancing insights into Lp(a) as a causal factor in CVD

3' education - June 29, 2018 - John Chapman - Paris, France

Emerging approaches to dyslipidemia management beyond LDL-c

3' education - Mar. 9, 2018 - VBWG at ACC 2018, Orlando, FL, USA - Eliot Brinton, Salt Lake City, UT, USA

Lipoprotein metabolism & CV risk: a long road from understanding to treatment

10' education - Jan. 6, 2017 - Prof. John JP Kastelein, Amsterdam, The Netherlands

Emerging therapeutic areas in lipid management and CV disease

3' education - Mar. 16, 2017 - VBWG - ACC 2017 - Sotirios Tsimikas - La Jolla, CA, USA

PCSK9 inhibitors: From bench to bedside

10' education - Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA

Elevated Lp(a) associated with large artery atherosclerosis stroke and risk of recurrent stroke

Literature - Mar. 23, 2021 - Arnold M et al. - Eur Heart J. 2021

The prospective BIOSIGNAL cohort study showed that elevated Lp(a) was independently associated with LAA stroke etiology and risk of recurrent AIS or TIA in patients <60 years.

Elevated Lp(a) associated with CAD in individuals without a family history of CVD

Literature - Mar. 8, 2021 - Finneran P et al. - J Am Heart Assoc. 2021

This study investigated the risk of incident CAD in participants from the UK Biobank with and without a family history of CVD in a sibling or parent.

E-learning Lp(a), a new lipid frontier in CV risk management

EBAC-accredited E-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

This online course covers different aspects of lipoprotein(a) (Lp(a)): the pathophysiology, its role in CVD risk and (novel) therapeutic options to reduce Lp(a) levels. This educational program is chaired by Erik Stroes, MD - Amsterdam, The Netherlands.

Total CV events lowered by PCSK9i-induced Lp(a) reduction in ACS patients

Literature - Nov. 6, 2020 - Szarek M, et al. - Eur Heart J. 2020

A post-hoc analysis of the ODYSSEY OUTCOMES trial found that Lp(a) reduction with alirocumab was, independent of LDL-c reduction, associated with reduced total CV events in ACS patients.

Introduction: Lp(a), a new lipid frontier in CV risk management & target for therapy

10' education - Nov. 3, 2020 - Prof. Erik Stroes, MD
Prof. Stroes gives an introduction to the symposium about different aspects of lipoprotein(a) (Lp(a)), that was held during the virtual ESC 2020 congress.

Prof. Stroes gives an introduction to the symposium about different aspects of lipoprotein(a) (Lp(a)), that was held during the virtual ESC 2020 congress.

Is there a role for PCSK9 inhibition in patients with high Lp(a)?

10' education - Nov. 2, 2020 - Prof. Vera Bittner, MD
Prof. Bittner summarizes findings from post-hoc analyses of FOURIER and ODYSSEY OUTCOMES on the relationship between Lp(a) lowering by PCSK9i and CV risk.

Prof. Bittner summarizes findings from post-hoc analyses of FOURIER and ODYSSEY OUTCOMES on the relationship between Lp(a) lowering by PCSK9 inhibition and CV risk.

Novel strategies to lower Lp(a)

10' education - Oct. 27, 2020 - Prof. Sam Tsimikas, MD
RNA therapeutics can reduce production of apo(a) in hepatocytes and thereby prevent assembly of Lp(a). This presentation provides an overview of phase 2 studies with antisense mediated Lp(a) lowering.

RNA therapeutics can reduce production of apo(a) in hepatocytes and thereby prevent assembly of Lp(a). This presentation provides an overview of phase 2 studies with antisense mediated Lp(a) lowering.

Latest results with non-LDL lowering agents in reducing CV risk

10' education - Oct. 26, 2020 - Prof. Ulrich Laufs, MD
Prof. Laufs discusses the role of triglycerides and Lp(a) in the context of residual risk.

Prof. Laufs discusses the role of triglycerides and Lp(a) in the context of residual risk.

Measured Lp(a) levels and LPA GRS similarly associated with ASCVD risk in primary prevention setting

News - Oct. 7, 2020

EAS 2020 In participants of the UK Biobank, a LPA genetic risk score and measured Lp(a) levels provided comparable risk prediction for ASCVD risk in a primary prevention setting.

Why worry about high Lp(a) and how to assess Lp(a) levels?

10' education - Oct. 7, 2020 - Pia Kamstrup, MD, PhD
High Lp(a) levels are associated with increased risk of CV events. Pia Kamstrup presents the evidence from studies and in addition talks about challenges when determining Lp(a) levels.

High Lp(a) levels are associated with increased risk of CV events. Pia Kamstrup presents the evidence from studies and in addition talks about challenges when determining Lp(a) levels.

Elevated Lp(a) and family history of CHD have independent and additive joint associations with CV events

Literature - Sep. 7, 2020 - Mehta A et al., - J Am Coll Cardiol. 2020.

This study evaluated the independent and joint associations of elevated Lp(a) and family history of CHD with incident ASCVD and CHD events among asymptomatic subjects.

Elevated Lp(a) levels associated with increased risk of MACE when hsCRP ≥2 mg/L

Literature - July 27, 2020 - Puri R et al., - JAMA Cardiol. 2020.

Elevated Lp(a) levels were associated with greater risk of MACE in optimally treated patients with high-risk vascular disease when hsCRP levels ≥2 mg/L, but not in those with hsCRP levels <2 mg/L.